Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

globenewswire.com
JNJ Mentioned as a key company in the psoriasis market, indicating involvement in the therapeutic area without specific performance details. PFE Listed as a key company in the JAK inhibitors market, suggesting its presence in psoriasis-related treatments. ABBV Identified as a key player in both JAK inhibitors and TNF-alpha inhibitors markets, relevant to psoriasis treatment. LLY Mentioned as a key company in TNF-alpha inhibitors and Interleukin-17 inhibitors markets, relevant to psoriasis treatment. AMGN Listed as a key company in the TNF-alpha inhibitors market, indicating its involvement in psoriasis-related therapies. INCY Listed as a key company in the JAK inhibitors market, relevant to psoriasis treatment. GILD Mentioned as a key company in the JAK inhibitors market, suggesting its involvement in psoriasis-related treatments. BHC Listed as a key company in the Interleukin-17 inhibitors market, relevant to psoriasis treatment. AZN Mentioned as a key company in the Interleukin-17 inhibitors market, indicating its involvement in psoriasis-related therapies. SUN Listed as a key company in the plaque psoriasis market, indicating its involvement in the therapeutic area.

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight New York, USA, April 14, 2026 (GLOBE NEWSWIRE) -- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

The psoriasis clinical trial analysis report delivers important insights into ongoing research of 100+ pipeline psoriasis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Psoriasis Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for psoriasis across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the psoriasis domain.

Psoriasis Clinical Trial Analysis Summary

Request a sample and discover the recent advances in psoriasis drug development @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

What is Psoriasis?

Psoriasis is a long-lasting, non-contagious condition in which the immune system mistakenly accelerates the life cycle of skin cells, causing them to build up rapidly on the surface. This leads to thick, red, inflamed patches of skin covered with silvery-white scales, commonly appearing on the elbows, knees, scalp, and lower back. The condition is driven by immune-mediated inflammation and is often associated with symptoms like itching, burning, and discomfort. While the exact cause is not fully understood, it is linked to a combination of genetic predisposition and environmental triggers such as stress, infections, or certain medications. Psoriasis can vary in severity and may also be associated with related conditions like psoriatic arthritis, affecting joints in some individuals.

Find out more about psoriasis drugs @ Psoriasis Treatment

A snapshot of the Pipeline Psoriasis Drugs mentioned in the report:

Learn more about the emerging psoriasis therapies @ Psoriasis Clinical Trials

According to Stuti Mahajan, consulting manager at DelveInsight, psoriasis continues to place a lasting burden on patients, driving the need for effective long-term management. Growing prevalence, better diagnosis, and rising demand for targeted, safer therapies are fueling market momentum, while ongoing innovation in biologics and novel treatments is set to sustain strong future growth.

Recent Developments in Psoriasis Treatment Space

Scope of the Psoriasis Pipeline Report

Dive deep into rich insights for new psoriasis treatments, visit @ Psoriasis Drugs

Table of Contents

For further information on the psoriasis cure research, reach out @ Medication for Psoriasis Treatment

Related Reports

Psoriasis Market

Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including Takeda, Nimbus Therapeutics, Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, Can-Fite BioPharma, Alumis, SFA Therapeutics, and others.

JAK Inhibitors Market

JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.

TNF-alpha Inhibitors Market

TNF-alpha Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha Inhibitors companies, including AbbVie, Amgen, Johnson & Johnson, Pfizer, UCB, Eli Lilly, Novartis, Merck, Sanofi, Boehringer Ingelheim, Samsung Bioepis, Celltrion, and others.

Interleukin-17 Inhibitors Market

Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-17 inhibitors companies, including MoonLake Immunotherapeutics, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics, Eli Lilly, UCB Pharma, Novartis, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, and others.

Plaque Psoriasis Market

Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key plaque psoriasis companies, including Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.